Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Finished Goods (2022 - 2025)

BioXcel Therapeutics has reported Finished Goods over the past 4 years, most recently at $37000.0 for Q4 2025.

  • Quarterly results put Finished Goods at $37000.0 for Q4 2025, down 78.61% from a year ago — trailing twelve months through Dec 2025 was $37000.0 (down 78.61% YoY), and the annual figure for FY2025 was $37000.0, down 78.61%.
  • Finished Goods for Q4 2025 was $37000.0 at BioXcel Therapeutics, down from $65000.0 in the prior quarter.
  • Over the last five years, Finished Goods for BTAI hit a ceiling of $1.4 million in Q2 2024 and a floor of $37000.0 in Q4 2025.
  • Median Finished Goods over the past 4 years was $595000.0 (2022), compared with a mean of $604466.7.
  • Biggest five-year swings in Finished Goods: soared 314.33% in 2023 and later plummeted 94.97% in 2025.
  • BioXcel Therapeutics' Finished Goods stood at $595000.0 in 2022, then tumbled by 31.93% to $405000.0 in 2023, then crashed by 57.28% to $173000.0 in 2024, then tumbled by 78.61% to $37000.0 in 2025.
  • The last three reported values for Finished Goods were $37000.0 (Q4 2025), $65000.0 (Q3 2025), and $73000.0 (Q2 2025) per Business Quant data.